MJB ADHD home · Guidebook

MJB ADHD · Static reading view · Interactive version

Source register

Status: drafted · Content checked 2026-10-06

Every source cited in the guide, with its type, what was actually read, and when it was checked.

1 · All sources

Case-record sources are listed by description only; the documents themselves are held privately and are not published here.

  1. W1 NICE. Attention deficit hyperactivity disorder: diagnosis and management (NG87). 2018, updated 2019. Recommendations 1.7.11–1.7.14 (adult medication choice) and section 1.10 (review and discontinuation). Source Official text via search snippets and NHS shared-care documents quoting it; main page fetch blocked

    Guidance shapes practice; it does not create an enforceable right to a particular medicine.

  2. W2 Li L, Zhu N, Zhang L, et al. ADHD pharmacotherapy and mortality in individuals with ADHD. JAMA 2024;331(10):850–860. Sweden, n=148,578, ages 6–64. Source Abstract and key results read (PubMed); full text open access

    Compares starting medication within 3 months of diagnosis with not starting. It is not a study of stopping an established treatment.

  3. W3 Zhang L, et al. ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. BMJ 2025;390:e083658. Sweden, n=148,581. A correction to figure 2 labels was published (PMC12401081). Source Abstract read in full (PubMed)

    Initiation versus non-initiation. Use the corrected figure.

  4. W4 Amfexa 5 mg, 10 mg and 20 mg Tablets, Summary of Product Characteristics (Medice UK). Section 4.1: ADHD in children and adolescents aged 6–17 when response to previous methylphenidate is clinically inadequate. Section 6.1 excipients: 10 mg — isomalt, magnesium stearate, yellow iron oxide; 20 mg — isomalt, magnesium stearate, red iron oxide; 5 mg — isomalt, crospovidone, magnesium stearate. Source Sections 4.1 and 6.1 checked (emc products 5004, 7403, 7404)

    Adult use is off-label and a specialist decision. Each strength has its own label.

  5. W5 Demontis D, et al. Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nature Genetics 2023;55:198–208. 38,691 cases, 186,843 controls. DOI Abstract read (PubMed)

    Associations at population level; not an individual diagnostic test.

  6. W6 Faraone SV, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews 2021;128:789–818. Source Abstract read; full text open access
  7. W7 Financial Times. The taxpayer-funded ADHD boom. 4 October 2026. Source Pointer from editorial handoff; summary only, not stored
  8. W8 NHS England. Report of the independent ADHD Taskforce, Part 2. 2025. Source Official search text; full page not recovered
  9. R1 Brams M, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with ADHD: randomized withdrawal design. J Clin Psychiatry 2012;73(7):977–83. Adults on lisdexamfetamine ≥6 months randomised to continue or switch to placebo for 6 weeks; n=116. DOI Abstract read (PubMed)

    The most direct evidence on stopping an established, working treatment in adults — but short (6 weeks) and measuring symptoms, not injury or death.

  10. R2 Cortese S, et al. Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018;5(9):727–738. 133 double-blind RCTs. DOI Abstract read (PubMed)
  11. R3 Hoogman M, et al. Subcortical brain volume differences in participants with ADHD in children and adults: a cross-sectional mega-analysis (ENIGMA). Lancet Psychiatry 2017;4(4):310–319. 1,713 ADHD, 1,529 controls. DOI Abstract read (PubMed)
  12. R4 Shaw P, et al. ADHD is characterized by a delay in cortical maturation. PNAS 2007;104(49):19649–54. 223 children with ADHD, 223 controls, 824 scans. DOI Abstract read (PubMed)
  13. R5 Volkow ND, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 2009;302(10):1084–91. 53 unmedicated adults with ADHD, 44 controls. DOI Abstract read (PubMed)
  14. R6 Fusar-Poli P, et al. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry 2012;169(3):264–72. Nine PET/SPECT studies. DOI Abstract read (PubMed)
  15. R7 Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Molecular Psychiatry 2019;24(4):562–575. DOI Abstract read (PubMed)
  16. R8 Sulzer D, et al. Mechanisms of neurotransmitter release by amphetamines: a review. Progress in Neurobiology 2005;75(6):406–33. DOI Abstract read (PubMed)
  17. R9 Arnsten AFT. Toward a new understanding of ADHD pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009;23 Suppl 1:33–41. DOI Abstract read (PubMed)
  18. R10 Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010;6:317–27. DOI Abstract read (PubMed)
  19. R11 O'Nions E, El Baou C, John A, et al. Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: matched cohort study. British Journal of Psychiatry 2025;226(5):261–268. 30,039 adults with diagnosed ADHD, 300,390 matched controls, UK primary care 2000–2019. DOI Abstract and multiple reports of results read; not via PubMed fetch
  20. R12 Pedroso JL, et al. SPG7 with parkinsonism responsive to levodopa and dopaminergic deficit. Parkinsonism Relat Disord 2017;47:88–90. Single case. DOI Abstract read (PubMed)
  21. R13 Pedroso JL, et al. Movement disorders in hereditary spastic paraplegias. Arq Neuropsiquiatr 2023;81(11):1000–1007. DOI Abstract read (PubMed)
  22. R14 Henssen D, et al. Subtle hypometabolism on [18F]FDG-PET, yet absent [123I]FP-CIT SPECT binding in a patient with spastic paraplegia type 7. EJNMMI Reports 2026;10(1). Single case. DOI Abstract read (PubMed)
  23. COR-2024-0699-WINSON Area Coroner for Norfolk. Regulation 28 Report to Prevent Future Deaths: Oliver Winson. Ref 2024-0699, 20 December 2024. Sent to NHS England. Source Coroner's report page read via search extract; download PDF to confirm wording before quoting
  24. P1 Bath and North East Somerset, Swindon and Wiltshire ICB. Shared Care Agreement: Methylphenidate, Atomoxetine, Lisdexamfetamine & Dexamfetamine (Amfexa) for ADHD – Adults. Version 3, approved April 2025. Source Full text read

    Another ICB's document. It shows practice exists elsewhere; it is not a rule for Coventry and Warwickshire.

  25. P2 Coventry and Warwickshire Partnership NHS Trust. Safeguarding Adults Policy, V5.0 (ref 710). Sections 3.7 (significant harm) and 3.8 (human rights). Supplied copy read

    A definition anchors a question; it does not by itself establish a statutory safeguarding duty or breach.

  26. P3 NHS Coventry and Warwickshire ICB. Policy for referral and assessment for ADHD for people under 25 (COM/46), V3, approved 2 April 2025. Supplied copy read

    Historical. Evidence of the route that existed while it was in force; not current policy.

  27. P4 Coventry and Warwickshire Partnership NHS Trust. Complaints Policy, V9.1. Review date 7 July 2026. Supplied copy read

    Check the current version for events after its review date.

  28. P5 Pulse. Care minister defends GP practices' right to decline ADHD shared care arrangements. 2025. Source Report read via earlier research; primary parliamentary answer not obtained
  29. L1 Information Commissioner's Office. Right of access (subject access requests), UK GDPR Article 15: one calendar month to respond, extendable in defined cases. Source Stable regulatory guidance; re-check before citing timelines
  30. N1 NHS — Dystonia Source Webpage read; not an independent systematic review
  31. N2 UCLH — Spasticity service Source Webpage read; not an independent systematic review
  32. N3 NHS — Ataxia Source Webpage read; not an independent systematic review
  33. N4 NHS — Peripheral neuropathy symptoms Source Webpage read; not an independent systematic review
  34. N5 IASP — Identifying neuropathic pain in the clinic Source Webpage read; not an independent systematic review
  35. N6 NHS Genomics Education — Hereditary spastic paraplegia Source Webpage read; not an independent systematic review
  36. N7 MedlinePlus Genetics — Dopa-responsive dystonia Source Webpage read; not an independent systematic review
  37. N8 NHS — Tiredness and fatigue Source Webpage read; not an independent systematic review
  38. N9 NHS — Adult developmental coordination disorder Source Webpage read; not an independent systematic review
  39. F1 Baziar et al. 2019. Saffron versus methylphenidate: six-week double-blind ADHD pilot, 54 children/adolescents randomised. DOI 10.1089/cap.2018.0146. Source Publisher abstract read; full paper not accessed
  40. F2 Cilia et al. 2018. Daily Mucuna in advanced Parkinson disease: 16-week crossover pilot. PMID 29352722. Source Indexed abstract/results retrieved through search; direct page incomplete
  41. F3 Cilia et al. Mucuna in untreated Parkinson disease in sub-Saharan Africa: 12-month randomised trial. Online November 2025; issue February 2026. DOI 10.1177/1877718X251383721. Source Publisher full text inspected: design, population, outcomes and adverse events
  42. F4 Cohen et al. 2022. Levodopa content of Mucuna supplements. JAMA Neurology. DOI 10.1001/jamaneurol.2022.2184. Source Full article read; 16 US commercial products, one sample per brand
  43. F5 DailyMed. Atomoxetine prescribing information: indication and mechanism. US product label. Source Relevant label sections read; US label is not UK prescribing authorisation
  44. F6 DailyMed. Guanfacine extended-release prescribing information: mechanism and safety. US product label. Source Official label opened; indication and mechanism sections inspected
  45. F7 DailyMed. Adderall mixed amphetamine salts prescribing information. US product label. Source Product composition and indication inspected; no claim about current UK availability
  46. F8 SAMHSA. Treatment for Stimulant Use Disorders, TIP 33 (2021), chapters 2 and 3: cocaine, methamphetamine, prescription stimulants. Source Relevant indexed passages retrieved; direct chapter page blocked. Full chapter not read
  47. F9 NICE NG71. Parkinson disease in adults: medication choices and impulse-control risks. Source Indexed recommendation passages checked; direct page fetch blocked
  48. F10 NHS. Parkinson disease: causes. Page last reviewed November 2022. Source Full webpage read; simplified explanation, not a complete pathogenesis review
  49. F11 NHS. Parkinson disease: diagnosis. Page last reviewed November 2022. Source Full webpage read
  50. F12 NHS. Parkinson disease: treatment. Page last reviewed November 2022. Source Full webpage read; general complementary-therapy wording predates trial F3
  51. F13 DailyMed. Desoxyn (methamphetamine hydrochloride) medication guide. US product label. Source Medication guide read; label existence does not establish current UK access
  52. F14 DailyMed. Ritalin (methylphenidate hydrochloride) prescribing information, section 12: reuptake mechanism. US label; not UK licensing evidence. Source Indexed official label mechanism passage inspected
  53. ACC-NHSE Official complaints routing in England Source Public official source reviewed; linked source controls its own later updates

    Source-specific finding or position. Does not establish every question in an individual case.

  54. ACC-CQC Regulations for service providers and managers Source Public official source reviewed; linked source controls its own later updates

    Source-specific finding or position. Does not establish every question in an individual case.

  55. ACC-HSSIB HSSIB, 13 May 2025: cross-system mental health inpatient safety findings Source Public official source reviewed; linked source controls its own later updates

    Source-specific finding or position. Does not establish every question in an individual case.

  56. ACC-RECS HSSIB: Recommendations to Impact Collaborative Group findings Source Public official source reviewed; linked source controls its own later updates

    Source-specific finding or position. Does not establish every question in an individual case.

  57. ACC-BETH Secretary of State case review into Beth, October 2019, published excerpt Source Public official source reviewed; linked source controls its own later updates

    Source-specific finding or position. Does not establish every question in an individual case.

  58. ACC-PHSO PHSO 2019: investigations of Matthew Leahy and Mr R Source Public official source reviewed; linked source controls its own later updates

    Source-specific finding or position. Does not establish every question in an individual case.

  59. ACC-LEAHY Lampard Inquiry: public commemorative and impact testimony Source Public official source reviewed; linked source controls its own later updates

    Source-specific finding or position. Does not establish every question in an individual case.

  60. RES-NHS NHS: ADHD in adults Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Official NHS patient information.

  61. RES-MEDICATION ADHD Direct: Is ADHD Medication Even Real? Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. A clinic-authored explainer; individual treatment decisions belong with your prescriber.

  62. RES-SHARED ADHD Direct: shared care explained Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. A private provider’s account, not a binding statement of the law or your local commissioning policy. Use alongside the transfer and handover route.

  63. RES-EMC Electronic medicines compendium (emc) Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Product-specific information. Bring questions about ingredients, side effects or instructions to your pharmacist or prescriber.

  64. RES-PMDD ADHD Direct: ADHD and PMDD Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Clinic-authored discussion. The link supplied under this title pointed to a different article; this is the matching public page.

  65. RES-PMDD-NHS NHS: PMDD Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Official patient information to accompany the provider’s ADHD/PMDD article.

  66. RES-DIRECT ADHD Direct Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Commercial clinical provider. Check current fees, terms and prescribing arrangements directly.

  67. RES-HOWTO How to ADHD — Jessica McCabe Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Creator-led educational content. The official site links its YouTube videos and playlists.

  68. RES-SCOTLAND Scottish ADHD Coalition Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Scottish support network; group availability and remit vary.

  69. RES-AADD AADD-UK Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. An adult ADHD community resource; check the date of individual pages and current group details.

  70. RES-UNDERSTOOD Understood Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. US-based resource. Its healthcare, employment and education rules are not UK rules.

  71. RES-ATW Access to Work Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Official guidance for England, Scotland and Wales. Eligibility and awarded support are assessed; Northern Ireland has a separate route.

  72. RES-DRIVING ADHD and driving — GOV.UK Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Official Great Britain guidance; use the linked rules for your licence category and circumstances.

  73. RES-ADD ADDitude Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. US-based commercial publication with advertising and paid material. Publication does not make every article a clinical guideline.

  74. RES-BARKLEY Taking Charge of Adult ADHD — Russell A. Barkley, with Christine M. Benton Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Second edition verified on the publisher’s page; paperback ISBN 9781462546855. A listing check is not a full review of the book.

  75. RES-HALLOWELL Driven to Distraction — Edward M. Hallowell and John J. Ratey Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Book listing checked on the author’s site. Check edition and date when discussing treatment information.

  76. RES-MATE Scattered Minds — Gabor Maté Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Listed in the supplied resource recommendations. An author’s explanatory framework is not established proof of ADHD causation; compare claims with the genetics and evidence routes.

  77. RES-HABITS Atomic Habits — James Clear Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. General habit advice, not an ADHD-specific clinical reference or evidence that disability can be overcome by willpower.

  78. RES-POD-ADULT The ADHD Adults Podcast Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Podcast format; individual episodes mix explanation and lived experience.

  79. RES-POD-ADD ADDitude ADHD Experts Podcast Source Publisher listing via search; direct fetch blocked

    Directory entry and intended use verified; not an independent review of all content. Publisher’s indexed listing verified through search; direct page access was blocked during this check. Check each speaker, date and any sponsorship.

  80. RES-FOREST Forest Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Optional commercial tool; check current platform, pricing and accessibility before installing.

  81. RES-TODOIST Todoist Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Optional organisation tool; start with a small list rather than an elaborate system.

  82. RES-SIMPLEMIND SimpleMind Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Optional commercial tool; check your device, export options and accessibility.

  83. RES-PRODUCTIVE Productive Source Originating public page checked

    Directory entry and intended use verified; not an independent review of all content. Optional commercial tool. Tracking should reduce effort rather than become another obligation.

  84. PD-SYM Parkinson’s UK: symptoms Source Full originating webpage read

    Sourced educational summary; not independent medical review.

  85. PD-GEN MedlinePlus Genetics: Parkinson’s disease Source Full originating webpage read

    Sourced educational summary; not independent medical review.

  86. PD-DIFF Parkinson’s UK: types of Parkinson’s and other causes of parkinsonism Source Full originating webpage read

    Sourced educational summary; not independent medical review.

  87. PD-SLEEP Parkinson’s UK: sleep Source Full originating webpage read

    Sourced educational summary; not independent medical review.

  88. PD-SWALLOW Parkinson’s UK: eating, swallowing and saliva Source Full originating webpage read

    Sourced educational summary; not independent medical review.

  89. PD-DRUGS Parkinson’s UK: medicines Source Full originating webpage read

    Sourced educational summary; not independent medical review.

  90. PD-DIARY Parkinson’s UK: symptom diaries Source Full originating webpage read

    Sourced educational summary; not independent medical review.

  91. PD-DBS Parkinson’s UK: deep brain stimulation Source Full originating webpage read

    Sourced educational summary; not independent medical review.

  92. PD-FAMILY Parkinson’s UK: family history and genes Source Full originating webpage read

    Sourced educational summary; not independent medical review.

  93. PD-TESTING Parkinson’s UK: NHS genetic testing routes Source Full originating webpage read

    Sourced educational summary; not independent medical review.

  94. PD-RESEARCH Parkinson’s UK: research and a cure Source Full originating webpage read

    Sourced educational summary; not independent medical review.

  95. PD-ONTIME Parkinson’s UK: Get It On Time Source Full originating webpage read

    Sourced educational summary; not independent medical review.

  96. FND-NHS NHS Inform: functional neurological disorder Source Indexed originating excerpts checked; direct fetch blocked

    Public source; full papers not independently reviewed. Distinguish consensus, primary and secondary trial outcomes.

  97. FND-KINGS King’s College Hospital: FND clinical service Source Full originating webpage read

    Public source; full papers not independently reviewed. Distinguish consensus, primary and secondary trial outcomes.

  98. FND-PHYSIO Nielsen et al. (2015): Physiotherapy for functional motor disorders, consensus recommendation Source Originating repository abstract read

    Public source; full papers not independently reviewed. Distinguish consensus, primary and secondary trial outcomes.

  99. FND-OT Nicholson et al. (2020): Occupational therapy consensus recommendations for FND Source PubMed abstract read

    Public source; full papers not independently reviewed. Distinguish consensus, primary and secondary trial outcomes.

  100. FND-SLT Baker et al. (2021): Functional communication, swallowing, cough and related disorders, SLT consensus Source PubMed abstract read

    Public source; full papers not independently reviewed. Distinguish consensus, primary and secondary trial outcomes.

  101. FND-TRIAL Nielsen et al. (2025): Outcomes of specialist physiotherapy for functional motor disorder, Physio4FMD report Source PubMed abstract read; 2024 originating trial repository also checked

    Public source; full papers not independently reviewed. Distinguish consensus, primary and secondary trial outcomes.

  102. FND-CODES Goldstein et al. (2020): Cognitive behavioural therapy for adults with dissociative seizures, CODES Source PubMed abstract read

    Public source; full papers not independently reviewed. Distinguish consensus, primary and secondary trial outcomes.

  103. AUTHOR-ACCOUNT Author’s account, published with the author’s authorization Personal account; not independently verified from public case documents

    No private-document identifiers, filenames, dates or document-level linkages are provided. This reference is not independent clinical evidence.

6 · Existing site library

Continue in the existing MJB library.

Uncertainty

Source inclusion is not endorsement of every interpretation. Access notes distinguish full-text checks, institutional explainers and material still needing verification.

Sources cited